A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg...

HemaSphere 2020 / 10 Vol. 4; Iss. 5

A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Lepik, Kirill V., Fedorova, Liudmila V., Kondakova, Elena V., Zalyalov, Yuri R., Babenko, Elena V., Lepik, Elena E., Kotselyabina, Polina V., Beynarovich, Anastasia V., Popova, Marina O., Volkov, Niki
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
4
Journal:
HemaSphere
DOI:
10.1097/hs9.0000000000000480
Date:
October, 2020
File:
PDF, 478 KB
2020
Conversion to is in progress
Conversion to is failed